Results 141 to 150 of about 31,914 (284)

Clinical Outcomes of Non Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Non Valvular Atrial Fibrillation Patients: A Cohort Study in a Rural Tertiary Care Hospital, Gujarat, India

Journal of Clinical and Diagnostic Research
Introduction: Atrial Fibrillation (AF) is the most common arrhythmia, with an increased risk of ischaemic stroke and subsequent morbidity and mortality. Oral anticoagulants such as Vitamin K Antagonists (VKAs) and non VKA Oral Anticoagulants (NOACs) are ...
Sohilkhan Riyazkhan Pathan, Bharat M Gajjar, Sunilkumar Karna, Kushal Pujara   +3 more
doaj   +1 more source

Dose‐Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta‐Analysis With Subgroup Exploration and Trial Sequential Validation

Clinical Cardiology, Volume 49, Issue 2, February 2026.
Efficacy and Safety of Factor XI/XIa Inhibitors vs DOAC in Atrial Fibrillation. ABSTRACT Background Factor XI/XIa inhibitors are emerging anticoagulants with potential to reduce bleeding complications in atrial fibrillation (AF) patients. This meta‐analysis evaluated their efficacy and safety compared to direct oral anticoagulants (DOACs) and explored ...
Muhammad Aqib Faizan, Tooba Rehman, Mrunalini Dandamudi, Jaivardhan A. Menon, Victoria Zecchin Ferrara, Zeyad Kholeif, Alina Tanvir, Fatima Saeed, Jibran Ikram, Moiuz Chaudhri, Carlos Espiche, Main Muhammad Salman Aslam, Zainab Humayun, Ahmad Mustafa Khalid, Saad Ahmad Waqas, Raheel Ahmad, Luis Cerna   +16 more
wiley   +1 more source

Bioactive Phenolic Compounds in Extra Virgin Olive Oil: Implications for Cardiovascular Health

Food Science &Nutrition, Volume 14, Issue 2, February 2026.
Extra virgin olive oil (EVOO) is rich in bioactive polyphenols that exert antioxidant, anti‐inflammatory, and anti‐atherogenic effects. These compounds improve endothelial function, modulate lipid metabolism, and reduce platelet aggregation, contributing to cardiovascular protection. Regular consumption of phenolic‐rich EVOO, as part of a Mediterranean
Cristina Vázquez‐Jiménez, Mª. Dolores Rodríguez‐Pérez, Laura Ortega‐Hombrados, Ana María Sánchez‐Tévar, José Pedro de la Cruz‐Cortés, José A. Gonzalez‐Correa   +5 more
wiley   +1 more source

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.

PLoS ONE, 2015
BackgroundUse of the non-vitamin K antagonist oral anticoagulants (NOACs) is endorsed by current guidelines for stroke prevention in patients with atrial fibrillation (AF).
Giuseppe Santarpia, Salvatore De Rosa, Alberto Polimeni, Salvatore Giampà, Mariella Micieli, Antonio Curcio, Ciro Indolfi   +6 more
doaj   +1 more source

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey

BJGP Open, 2018
Background: Familiarity and competency in the options for stroke prevention in atrial fibrillation (AF) and the role of non-vitamin K antagonist oral anticoagulants (NOACs) may vary among primary care physicians (PCPs) from different European countries ...
Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan Polo Friz, David Fitzmaurice, FD Richard Hobbs   +5 more
doaj   +1 more source

Skeletal Muscle Mass Modifies the Prognostic Impact of LDL Cholesterol in Chronic Heart Failure

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Dyslipidaemia is among the major risk factors for atherosclerotic cardiovascular disease. Paradoxically, higher cholesterol levels are associated with better survival in heart failure (HF) of any aetiology. Because cholesterol is an integral component of skeletal muscle structure, one possible explanation involves the interplay ...
Ryosuke Sato, Tania Garfias‐Veitl, Guglielmo Fibbi, Mirela Vatic, Wolfram Doehner, Stefan D. Anker, Stephan von Haehling   +6 more
wiley   +1 more source

Safety and Efficacy of Pulsed Field Ablation for Atrial Fibrillation in Elderly Patients

Journal of Arrhythmia, Volume 42, Issue 1, February 2026.
Pulsed‐field ablation (PFA) was evaluated in 479 patients with atrial fibrillation (AF), 52% paroxysmal. Among 104 patients > 75 years, complication rates and 6‐ and 12‐month arrhythmia‐free survival were not significantly different from younger patients. Age did not predict recurrence. PFA appears safe and effective in elderly AF patients.
Federico Follesa, Alix Prévot, Samy Gribissa, Xavier Waintraub, Marine Thuillot, Nicolas Badenco, Guillaume Duthoit, Estelle Gandjbakhch, Mikael Laredo   +8 more
wiley   +1 more source

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer

Korean Circulation Journal, 2018
Background and Objectives There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer.
Kyu Kim, Yong Joon Lee, Tae Hoon Kim, J. Uhm, H. Pak, Moon‐Hyoung Lee, B. Joung   +6 more
semanticscholar   +1 more source

One‐Year Outcome of Japanese Patients With Atrial Fibrillation: Insights From APHRS‐AF Registry

Journal of Arrhythmia, Volume 42, Issue 1, February 2026.
A total of 794 patients recruited from 28 large cardiovascular centers in Japan were prospectively investigated. Patients were relatively young, had low CHADS2 scores, and relatively few comorbidities such as hypertension. Majority of the patients were scheduled for catheter ablation. Short‐term prognosis was found to be extremely favorable.
Kenji Yodogawa, Yu‐ki Iwasaki, Yasuo Okumura, Koichi Nagashima, Koichi Inoue, Nobuaki Tanaka, Kengo Kusano, Koji Miyamoto, Masahiko Takagi, Kyoko Soejima, Yuichi Momose, Tomohiro Sakamoto, Hideharu Okamatsu, Toyoaki Murohara, Yasuya Inden, Keiichi Fukuda, Seiji Takatsuki, Yasuki Kihara, Yukiko Nakano, Teiichi Yamane, Michifumi Tokuda, Masayoshi Ajioka, Hiroyuki Osanai, Kazuhiro Satomi, Hiroyuki Tsutsui, Akihiko Shimizu, Satoru Sakagami, Eiichi Watanabe, Nobuhisa Hagiwara, Mitsuharu Kawamura, Naohiko Takahashi, Yoshinori Kobayashi, Hirofumi Tomita, Hiroshi Tada, Kazutaka Aonuma, Yukihiro Koretsune, Takanori Ikeda, Masahiko Goya, Wataru Shimizu   +38 more
wiley   +1 more source

Proper dosing and key drug interactions of the non-vitamin K antagonist oral anticoagulants. Summary from the 2024 European Society of Cardiology (ESC) Guidelines

Cardiologia Hungarica
The use of non-vitamin K antagonist oral anticoagulants (NOACs) has become a cornerstone of stroke prevention in patients with atrial fibrillation. This brief summary, based on the latest European guidelines, aims to summarize the appropriate dosing ...
Letícia Kazareczki, Máté Vámos
doaj   +1 more source